Synonym
GQC-05; GQC05; GQC 05; NSC338258; NSC 338258; NSC-338258;
IUPAC/Chemical Name
2-((5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-yl)oxy)-N,N-dimethylethan-1-amine
InChi Key
FGFDMBHOYCMKEJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H23N3O/c1-13-18-12-22-8-7-16(18)14(2)21-20(13)17-11-15(5-6-19(17)23-21)25-10-9-24(3)4/h5-8,11-12,23H,9-10H2,1-4H3
SMILES Code
CC1=C(C=NC=C2)C2=C(C)C(N3)=C1C4=C3C=CC(OCCN(C)C)=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
333.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Montoya JJ, Turnidge MA, Wai DH, Patel AR, Lee DW, Gokhale V, Hurley LH, Arceci RJ, Wetmore C, Azorsa DO. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells. BMC Cancer. 2019 Dec 27;19(1):1251. doi: 10.1186/s12885-019-6464-9. PMID: 31881855; PMCID: PMC6935221.
2: Weldon C, Dacanay JG, Gokhale V, Boddupally PVL, Behm-Ansmant I, Burley GA, Branlant C, Hurley LH, Dominguez C, Eperon IC. Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X. Nucleic Acids Res. 2018 Jan 25;46(2):886-896. doi: 10.1093/nar/gkx1122. PMID: 29156002; PMCID: PMC5778605.
3: Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. J Med Chem. 2017 Aug 10;60(15):6587-6597. doi: 10.1021/acs.jmedchem.7b00298. Epub 2017 Jul 25. PMID: 28605593.
4: Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem. 2011 Nov 25;286(47):41018-27. doi: 10.1074/jbc.M111.274720. Epub 2011 Sep 28. PMID: 21956115; PMCID: PMC3220475.
5: Tian E, Landowski TH, Stephens OW, Yaccoby S, Barlogie B, Shaughnessy JD Jr. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma. Mol Cancer Ther. 2008 Mar;7(3):500-9. doi: 10.1158/1535-7163.MCT-07-0524. Epub 2008 Mar 4. PMID: 18319333.
